DE602004021567D1 - Antikörper gegen tumorspezifisches antigen als ziel - Google Patents

Antikörper gegen tumorspezifisches antigen als ziel

Info

Publication number
DE602004021567D1
DE602004021567D1 DE602004021567T DE602004021567T DE602004021567D1 DE 602004021567 D1 DE602004021567 D1 DE 602004021567D1 DE 602004021567 T DE602004021567 T DE 602004021567T DE 602004021567 T DE602004021567 T DE 602004021567T DE 602004021567 D1 DE602004021567 D1 DE 602004021567D1
Authority
DE
Germany
Prior art keywords
cancer
goal
antibodies against
specific antigen
against tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004021567T
Other languages
English (en)
Inventor
Kimihisa Ichikawa
Shu Takahashi
Toshinori Agatsuma
Keisuke Fukuchi
Takehiro Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE602004021567D1 publication Critical patent/DE602004021567D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DE602004021567T 2003-03-10 2004-03-09 Antikörper gegen tumorspezifisches antigen als ziel Expired - Lifetime DE602004021567D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003063648 2003-03-10
PCT/JP2004/003048 WO2004081050A1 (ja) 2003-03-10 2004-03-09 癌特異的抗原を標的とした抗体

Publications (1)

Publication Number Publication Date
DE602004021567D1 true DE602004021567D1 (de) 2009-07-30

Family

ID=32984436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021567T Expired - Lifetime DE602004021567D1 (de) 2003-03-10 2004-03-09 Antikörper gegen tumorspezifisches antigen als ziel

Country Status (20)

Country Link
US (4) US7855056B2 (de)
EP (1) EP1602669B1 (de)
JP (1) JP4462964B2 (de)
KR (1) KR20050116374A (de)
CN (2) CN102151334A (de)
AT (1) ATE434044T1 (de)
AU (1) AU2004220182B2 (de)
BR (1) BRPI0408238A (de)
CA (1) CA2518787A1 (de)
DE (1) DE602004021567D1 (de)
DK (1) DK1602669T3 (de)
ES (1) ES2327408T3 (de)
HK (1) HK1078593A1 (de)
MX (1) MXPA05009715A (de)
NO (1) NO20054631L (de)
NZ (1) NZ542220A (de)
RU (1) RU2345090C2 (de)
TW (1) TW200508249A (de)
WO (1) WO2004081050A1 (de)
ZA (1) ZA200507298B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1639000A2 (de) * 2003-07-02 2006-03-29 Genentech, Inc. Zusammensetzungen und verfahren für die tumor-diagnose und -behandlung
US20110194996A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Transport container for stabilized liquid samples
CN103168377A (zh) 2010-11-05 2013-06-19 株式会社Lg化学 具有改善的安全性的二次电池
EP2589609A1 (de) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
US20140224373A1 (en) * 2013-02-12 2014-08-14 MPS Enterprises, Inc. Lay-flat hose for oilfield hydraulic fracturing operations
KR102536786B1 (ko) * 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Ｃｄ７３ 차단
KR20200057157A (ko) * 2018-11-15 2020-05-26 삼성디스플레이 주식회사 레이저 장치 및 이를 이용한 기판 식각 방법
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5728821A (en) 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
CA2331998A1 (en) 1998-05-08 1999-11-18 Toyama Chemical Co., Ltd. Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
IL147765A0 (en) * 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002016603A2 (en) * 2000-08-21 2002-02-28 Millennium Pharmaceuticals, Inc. 23228, a novel human tetraspanin family member and uses thereof
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005518782A (ja) * 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1639000A2 (de) 2003-07-02 2006-03-29 Genentech, Inc. Zusammensetzungen und verfahren für die tumor-diagnose und -behandlung

Also Published As

Publication number Publication date
CN1784426A (zh) 2006-06-07
RU2345090C2 (ru) 2009-01-27
AU2004220182B2 (en) 2007-12-06
ATE434044T1 (de) 2009-07-15
NO20054631L (no) 2005-12-09
NZ542220A (en) 2008-04-30
AU2004220182A1 (en) 2004-09-23
US20070025996A1 (en) 2007-02-01
CA2518787A1 (en) 2004-09-23
US20060127405A1 (en) 2006-06-15
DK1602669T3 (da) 2009-09-14
ES2327408T3 (es) 2009-10-29
JP2004290187A (ja) 2004-10-21
US20080146785A1 (en) 2008-06-19
EP1602669B1 (de) 2009-06-17
WO2004081050A1 (ja) 2004-09-23
US7741447B2 (en) 2010-06-22
TW200508249A (en) 2005-03-01
NO20054631D0 (no) 2005-10-07
HK1078593A1 (en) 2006-03-17
KR20050116374A (ko) 2005-12-12
CN102151334A (zh) 2011-08-17
BRPI0408238A (pt) 2006-03-01
ZA200507298B (en) 2006-06-28
US7361340B2 (en) 2008-04-22
EP1602669A4 (de) 2006-08-09
MXPA05009715A (es) 2005-10-18
US7855056B2 (en) 2010-12-21
JP4462964B2 (ja) 2010-05-12
RU2005128277A (ru) 2006-06-10
US20070166312A1 (en) 2007-07-19
EP1602669A1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
WO2003080582A3 (de) Fredericamycin-derivate
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
HK1094167A1 (en) Monoclonal antibodies to hepatocyte growth factor
AU6469601A (en) Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
HK1078593A1 (en) Antibody against a tumor-specific antigen as target
CY1106879T1 (el) Χρηση των αναστολεων αναγωγασης συνενζυμου α 3-υδροξυ-3-μεθυλογλουταρυλ για την παρασκευη ενος φαρμακου για την αντιμετωπιση της διαβητικης νευροπαθειας
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EP1855719A4 (de) Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
NO20055209L (no) Peptabody for cancerbehandling
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
DE602004027086D1 (de) Klassifizierung von kolonkrebs
DE502005006028D1 (de) Homöpathisches mittel zur prophylaxe gegen von parasiten hervorgerufenen krankheiten
AU2003206144A1 (en) Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof
BG108945A (en) FIELD OF APPLICATION FOR ANTIGEN-BINDING ACTIVITY OF IMMUNOGLOBULIN PREPARATIONS

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAIICHI SANKYO CO., LTD., TOKYO, JP

8364 No opposition during term of opposition